noromectin (noromectin pour-on) áhella, lausn 0,5 % w/v
norbrook laboratories (ireland) limited - ivermectinum inn - Áhella, lausn - 0,5 % w/v
selevitan, vet. stungulyf, lausn
boehringer ingelheim animal health nordics a/s - natrii selenis; tocopherolum (alfa) acetat - stungulyf, lausn
peditrace innrennslisþykkni, lausn
fresenius kabi ab - manganosi chloridum; cupri chloridum; natrii selenas; kalii iodidum; zinci chloridum; natrii fluoridum - innrennslisþykkni, lausn
baycox iron
bayer animal health gmbh - iron(iii) ion, toltrazuril - toltrazuril, sturtu - svín (smágrísir) - fyrir samhliða fyrirbyggja klínískum merki um hníslasótt (eins og niðurgangur) í nýbura grísi á býli með staðfest sögu hníslasótt af völdum cystoisospora am, og koma í veg fyrir járn skort blóðleysi.
revolade
novartis europharm limited - eltrombopag - purpura, blóðflagnafæð, blóðflagnafæð - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 og 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 og 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.
forceris
ceva santé animale - toltrazuril, járn (iii) jón - toltrazuril, sturtu - svín (smágrísir) - fyrir aðra fyrirbyggja járn skort blóðleysi og koma í veg fyrir klínískum merki um hníslasótt (niðurgangur) eins og lækkun í oocyst skilst, í grísi í bæjum með staðfest sögu hníslasótt af völdum cystoisospora am.
xofluza
roche registration gmbh - baloxavir marboxil - inflúensu, manna - veirueyðandi lyf til almennrar notkunar - treatment of influenzaxofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. post exposure prophylaxis of influenzaxofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. xofluza should be used in accordance with official recommendations.
uniferon stungulyf, lausn 200 mg/ml
pharmacosmos a/s* - ferri hydroxidum dextran komplex - stungulyf, lausn - 200 mg/ml
ariclaim
eli lilly nederland b.v. - duloxetin - sykursýkis taugakvilla - psychoanaleptics, - meðferð við útlægum taugakvillaverkjum í sykursýki. ariclaim er ætlað í fullorðnir.
sabervel
pharmathen s.a. - irbesartan - háþrýstingur - lyf sem hafa áhrif á renín-angíótensín kerfið - sabervel er ætlað fullorðnum til meðferðar við nauðsynlegum háþrýstingi. Það er einnig ætlað til meðferð nýrnasjúkdóm í fullorðinn sjúklinga með blóðþrýsting og tegund 2 sykursýki sem hluti af blóðþrýstingslækkandi lyf meðferð.